
DataMSA Survey Representing Individuals Lost to MSA (Multiple System Atrophy)
The purpose of this survey was to collect data and information from individuals who are currently living with Multiple System Atrophy (MSA), and from caregivers and loved ones of those lost to MSA.
The data collected through this survey was made available, at no cost, to groups, agencies and medical personnel providing treatment, education and research for MSA.
IMPORTANT:
– Please do not respond to this survey if the individual has/had not received a formal diagnosis of MSA.
– Please respond ONLY ONCE per individual living with or lost to MSA.
– All respondents will remain confidential.
| who is completing this survey | |
|---|---|
| Person living with MSA | 318 |
| Caregiver/loved one of an individual currently living with MSA | 388 |
| Caregiver/loved one of an individual lost to MSA | 123 |
Background Information:
In which country/region does/did the individual reside? 829 responses
| Region | responses |
|---|---|
| Region I: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont | 39 |
| Region II: New Jersey, New York, Puerto Rico, Virgin Islands | 40 |
| Region III: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia | 50 |
| Region IV: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee | 106 |
| Region V: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin | 98 |
| Region VI: Arkansas, Louisiana, New Mexico, Oklahoma, Texas | 76 |
| Region VII: Iowa, Kansas, Missouri, Nebraska | 31 |
| Region VIII: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming | 14 |
| Region IX: Arizona, California, Hawaii, Nevada (American Samoa, Guam, Northern Mariana Islands, Trust Territory of the Pacific Islands) | 53 |
| Region X: Alaska, Idaho, Oregon, Washington | 48 |
| Region XI: Canada | 38 |
| Region XII: Central America | 2 |
| Region XIII: Asia | 15 |
| Region XIV: Africa | 13 |
| Region XV: South America | 1 |
| Region XVI: Antarctica | 1 |
| Region XVII: Europe | 86 |
| Region XVIII: Australia (continent), New Zealand | 72 |
| Region XVIII: Australia (continent) | 30 |
| Region I: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermon | 16 |
What is/was the individual’s gender? 829 responses
| Gender | Responses |
|---|---|
| male | 486 |
| female | 343 |
Diagnosis Data:
At what age was the individual diagnosed with MSA? 829 responses
| Age at diagnosis | Responses |
|---|---|
| 20-25 | 0 |
| 26-30 | 1 |
| 31-35 | 3 |
| 36-40 | 11 |
| 41-45 | 28 |
| 46-50 | 75 |
| 51-55 | 158 |
| 56-60 | 179 |
| 61-65 | 180 |
| 66-70 | 106 |
| 71-75 | 63 |
| 76-80 | 16 |
| 80 or older | 9 |
With which type of MSA was the individual diagnosed? 829 responses
| Type of multiple system atrophy | resonses |
|---|---|
| MSAc | 364 |
| MSAp | 237 |
| uncertain | 228 |
How long did it take for the individual to secure a Probable/likely diagnosis of MSA? 823 responses
| Time to secure Probable/likely MSA diagnosis | responses |
|---|---|
| 0-6 months | 98 |
| 6-12 months | 129 |
| 12-18 months | 137 |
| 18-24 months | 110 |
| 24 or more months | 349 |
How many neurologists did the individual consult during the diagnosis process? 826 responses
| number of neurologists | responses |
|---|---|
| 1 | 116 |
| 2 | 264 |
| 3 | 244 |
| 4 | 122 |
| 5 or more | 77 |
| I have not been seen by a neurologist | 3 |
Was the individual diagnosed with any condition(s)/illness(es) prior to receiving a diagnosis of MSA? 820 responses
| other diagnosis | responses |
|---|---|
| no | 231 |
| yes | 589 |
At what age did the individual first notice symptoms, later attributed to MSA? 824 responses
| age at first Symptoms | responses |
|---|---|
| 20-25 | 3 |
| 26-30 | 4 |
| 31-35 | 9 |
| 36-40 | 25 |
| 41-45 | 62 |
| 46-50 | 135 |
| 51-55 | 174 |
| 56-60 | 187 |
| 61-65 | 130 |
| 66-70 | 65 |
| 71-75 | 23 |
| 76-80 | 5 |
| 80 or older | 2 |
Please indicate events which cause/caused the individual’s MSA symptoms to worsen? 798 responses
Are/Were any cycles observed with regard to periods of worsening of the individual’s symptoms? 774 responsesn
| yes/no | Respondents |
|---|---|
| no | 500 |
| yes | 274 |
If cycles are/were observed with regard to worsening of the individual’s symptoms, on average, what was the frequency of the cycles? 319
| Frequency | Respondents |
|---|---|
| approximately twice a week | 76 |
| approximately once a week | 67 |
| approximately twice a month | 47 |
| approximately once a month | 66 |
| less frequently than once a month | 63 |
If cycles are/were observed with regard to worsening of the individual’s symptoms, what was the duration of the cycle? 307
| Duration | Respondents |
|---|---|
| less than 6 hours | 44 |
| 6-12 hours | 38 |
| 13-18 hours | 8 |
| 19-24 hours | 15 |
| one to two days | 81 |
| more than two full days | 121 |
Are/Were there any strategies/interventions that help(ed) reduce the individual’s symptoms? 710 responses
| yes/no | respondents |
|---|---|
| no | 313 |
| yes | 397 |
If yes, what are/were the strategies/interventions that help(ed) reduce the individual’s symptoms? 420 responses
| Strategy/intervention | respondents |
|---|---|
| Diet | 144 |
| Exercise/Physical Activity | 246 |
| Physical Therapy/ Movement Therapy | 260 |
| Accupuncture | 27 |
| Light Therapy | 14 |
| Speech Therapy | 172 |
| Supplements (please describe below) | 71 |
| Socialization | 129 |
| Games, Puzzles, etc. | 75 |
Neurological Care:
On average, what is/was the frequency of the individual’s neurological care? 814 responses
| frequency | respondents |
|---|---|
| less than once a year | 61 |
| once a year | 69 |
| twice a year | 236 |
| three or more times a year | 391 |
| no neurological care since diagnosis | 57 |
Has/Had the individual participated in clinical research regarding MSA? 810 responses
| yes/no | respondents |
|---|---|
| no | 717 |
| yes | 93 |
In the past/last year, how would you describe the rate of progression of the individual’s MSA illness? 793 responses
| Rate of progression | respondents |
|---|---|
| (1) very few signs of any progression in the past/last year | 21 |
| (2) some subtle signs of progression in the past/last year | 77 |
| (3) definite signs of progression in the past/last year | 389 |
| (4) rapid progression in the past/last year | 306 |
Living Conditions:
Does/Did the individual receive adequate support to live comfortably? 775 responses
| yes/no | respondents |
|---|---|
| yes | 695 |
| no | 80 |
If the individual was lost to MSA, how long after MSA diagnosis did he/she live? 133 responses
| one year | 5 |
| two years | 13 |
| three years | 33 |
| four years | 17 |
| five years | 14 |
| six years | 6 |
| seven years | 5 |
| eight years | 5 |
| nine years | 7 |
| ten years | 7 |
| Still living | 2 |
| 9 months | 2 |
If the individual was lost to MSA, please indicate the cause of death: 123 blockage1/511.4%26.8%30.9%
| Cause of death | Respondents |
|---|---|
| Respiratory failure (stopped breathing) | 38 |
| Respiratory infection (e.g.: pneumonia) | 33 |
| Respiratory blockage (choking, obstruction) | 7 |
| Heart attack | 1 |
| Stroke | 2 |
| Other complications from blood clot(s) | 2 |
| Digestive system failure (unable to digest food) | 2 |
| Digestive system blockage | 14 |
| Head injury due to fall | 0 |
| Other injury due to fall | 0 |
If the individual was lost to MSA, what was his/her age at the time of death? 131 responses
| Age at time of death | respondents |
|---|---|
| 20-25 | 0 |
| 26-30 | 0 |
| 31-35 | 3 |
| 36-40 | 1 |
| 41-45 | 0 |
| 46-50 | 4 |
| 51-55 | 7 |
| 56-60 | 19 |
| 61-65 | 36 |
| 66-70 | 30 |
| 71-75 | 22 |
| 76-80 | 6 |
| 81-85 | 1 |
| 86-90 | 1 |
| 90 or older | 1 |
Has/Had the individual made arrangements to donate his/her brain to an agency for Research? 654 response
| yes/no | respondents |
|---|---|
| No | 525 |
| Yes | 129 |
Does/Did the individual with MSA support a “patient’s right to die?” 719 responses
| yes/no | respondents |
|---|---|
| no | 72 |
| yes | 420 |
| uncertain/undecided | 227 |
Thank you for taking the time to complete this survey – your input is invaluable for those involved in MSA research, education and awareness.


Ciarán Walsh
Research Assistant
Sensors, Data cleaning, Field logistics

Daniel Okeke
MSc Student
Environmental justice, Interviews, Mapping
PhD Researcher
Water access, Community research, GIS

Amina El-Khoury
Postdoctoral Fellow
Coastal change, Risk, Mixed methods

Visiting Collaborators
Network
Partnerships, Coauthorship, Shared datasets
Funding & Partners
NotesLab® is supported by:
In collaboration with:
F.A.Q.
What’s the difference between Field Notes and Publications?
Field Notes are working-facing posts—method notes, reflections, and updates written for readability and practical reuse. Publications are formal research outputs (journal articles, reports, and working papers) with citation details and official links.
Can I reuse your datasets, protocols, or templates?
Often, yes. Each resource lists its license and any access conditions. If a dataset is restricted (e.g., sensitive locations or participant privacy), we’ll note how to request access.
How should I cite something from this site?
Use the citation information on the relevant page when available (publication citation, dataset version, or post date).
When in doubt, cite the page title, NotesLab®, the year, and the URL.
How do I collaborate or request access to restricted materials?
Email noteslab@dier.ie with a short description of your project and what you need (e.g., dataset version, intended use, timeline). We typically respond within 3–5 working days.